Last reviewed · How we verify

1 month Rifapentine, Isoniazid and Vitamin B6

Rutgers, The State University of New Jersey · FDA-approved active Small molecule Quality 5/100

1 month Rifapentine, Isoniazid and Vitamin B6 is a Small molecule drug developed by Rutgers, The State University of New Jersey. It is currently FDA-approved.

At a glance

Generic name1 month Rifapentine, Isoniazid and Vitamin B6
SponsorRutgers, The State University of New Jersey
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about 1 month Rifapentine, Isoniazid and Vitamin B6

What is 1 month Rifapentine, Isoniazid and Vitamin B6?

1 month Rifapentine, Isoniazid and Vitamin B6 is a Small molecule drug developed by Rutgers, The State University of New Jersey.

Who makes 1 month Rifapentine, Isoniazid and Vitamin B6?

1 month Rifapentine, Isoniazid and Vitamin B6 is developed and marketed by Rutgers, The State University of New Jersey (see full Rutgers, The State University of New Jersey pipeline at /company/rutgers-the-state-university-of-new-jersey).

What development phase is 1 month Rifapentine, Isoniazid and Vitamin B6 in?

1 month Rifapentine, Isoniazid and Vitamin B6 is FDA-approved (marketed).

Related